Latest News on Estrogen and Alzheimer's Disease - FabuVag® cream - Vaginal Moisturizer
IMG_1926.jpg

Latest News on Estrogen and Alzheimer’s Disease

A recent study published in the Public Library of Science (PLOS) suggests that Menopause is associated with brain changes that may increase the risk for Alzheimer’s disease (AD).

According to this study, Perimenopausal and postmenopausal women showed lower brain metabolism compared to premenopausal women in the same parts of the brain.

These findings suggest that aging inside the brain starts several years or even decades before possible clinical symptoms show up. This study was published on October 10, 2017 in PLOS One.

“Our findings show that the loss of estrogen in menopause doesn’t just diminish fertility. This study suggests there may be a critical window of opportunity, when women are in their 40s and 50s, to detect metabolic signs of higher Alzheimer’s risk and apply strategies to reduce that risk,” Lisa Mosconi, PhD, associate director of the Alzheimer’s Prevention Clinic at Weill Cornell Medicine in New York City, said in a news release.

Advanced age is the first and most important risk factor for developing AD. Being a woman is the second most important risk factor for Alzheimer’s disease.

The finding from this study suggest that Estrogen plays a major role in the development of AD.

There has been so much controversy around the usage of hormones in peri-menopausal and post-menopausal women. When choosing a treatment option, you and your healthcare provider should consider the risks and benefits of HRT. For more information on making choices about hormone replacement therapy, you may refer to hormone therapy expert such as Dr. Sharzad Green, Pharm.D.

 

 


Leave a Reply

Your email address will not be published. Required fields are marked *


FabuVag® cream - Vaginal Moisturizer
Assign a menu in the Left Menu options.
Assign a menu in the Right Menu options.